Noile-Immune Biotech News

Noile-Immune Biotech: Correction Confirmation Form

Oct 14 23:07 ET

Noile-Immune Biotech: Revised Semi-Annual Report - Term 10 (2024/01/01 to 2024/12/31)

Oct 14 23:06 ET

Noile-Immune Biotech: (Correction) Partial Corrections to the “Notice Concerning Prioritization of Our Drug Discovery Pipeline and Associated Changes in the Use of Funds Raised at the Time of Listing”

Oct 11 04:00 ET

Noile-Immune Biotech: Notice regarding a business alliance with Takara Bio Co., Ltd. for the development of NIB103

Sep 25 02:00 ET

Noile-Immune Biotech: Semi-Annual Report - Term 10 (2024/01/01 - 2024/12/31)

Aug 12 23:02 ET

Noile-Immune Biotech: Confirmatory letter.

Aug 12 23:00 ET

Noile-Immune Biotech: 2nd quarter (interim) financial report for the fiscal year ending December 2024 [Japan Standard] (non-consolidated)

Aug 9 04:45 ET

Noile-Immune Biotech: Change Report

Jul 31 03:05 ET

Noile-Immune Biotech: Change report.

Jul 26 03:05 ET

Noile-Immune Biotech: Announcements of individual stocks regarding the re-prioritization of our in-house drug development pipeline and changes in the use of funds raised at the time of listing.

Jun 28 04:00 ET

Noile-Immune Biotech: Regarding the return of NIB102 and NIB103 to Takeda Pharmaceutical.

Jun 23 20:12 ET

Noile-Immune Biotech: Change report.

Jun 21 02:15 ET

Noile-Immune Biotech: Change Report

May 24 01:51 ET

Noile-Immune Biotech: Confirmation letter

May 14 04:07 ET

Noile-Immune Biotech: Quarterly Report - 10th Quarter 1st Quarter (2024/01/01 - 2024/03/31)

May 14 04:05 ET

Noile-Immune Biotech: Summary of financial results for the 1st quarter of the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)

May 14 04:00 ET

Neurimune Biotech: Extraordinary Report

Apr 2 00:49 ET

Noile-Immune Biotech: Corporate Governance Report 2024/03/29

Mar 29 06:57 ET

Noile-Immune Biotech: Matters relating to business plans and growth potential

Mar 29 03:30 ET

Neurimune Biotech: Confirmation

Mar 29 01:19 ET